MorphoSys AG

Type: Company
Name: MorphoSys AG
Nationality: Germany
Web Address: http://www.morphosys.com/
First reported Jun 07 2013 - Updated Jun 07 2013 - 2 reports

MorphoSys, GSK ink license agreement

Pharmaceutical developer MorphoSys has entered into a global agreement with GlaxoSmithKline to develop and commercialize MOR103, MorphoSys's proprietary HuCAL-derived antibody against GM-CSF, which has concluded phase I/II development in mild to moderate ... [Published Center Watch - Jun 07 2013]
First reported Jun 06 2013 - Updated Jun 06 2013 - 1 reports

GSK buys rights to MorphoSys’ arthritis antibody

Pharma company will pay up €445m to develop and commercialise MOR103GlaxoSmithKline (GSK) has agreed to pay up to €445m to acquire the rights to an investigational rheumatoid arthritis (RA) and multiple sclerosis (MS) candidate from MorphoSys.Known as ... [Published PMLive - Jun 06 2013]
First reported Jun 06 2013 - Updated Jun 06 2013 - 1 reports
GlaxoSmithKline plc
GlaxoSmithKline plc

Glaxo, MorphoSys in $577M RA Deal

MorphoSys Signs Global License Agreement with GlaxoSmithKline for Anti-Inflammatory Program MOR103 MorphoSys to Receive Committed and Success-based Payments of up to EUR 445 Million and Double-digit Royalties on Net Sales  ... ... [Published Drugs.com - Jun 06 2013]
First reported Jun 05 2013 - Updated Jun 05 2013 - 2 reports

GSK to develop and commercialize MorphoSys HuCAL-derived antibody

GlaxoSmithKline (GSK) has agreed to assume responsibility for all development and commercialization of MorphoSys' proprietary HuCAL-derived antibody against GM-CSF, MOR103. MOR103 has concluded Phase 1/2 development in mild to moderate rheumatoid arthritis. ... [Published Big News Network - Jun 05 2013]
First reported Jun 04 2013 - Updated Jun 04 2013 - 1 reports
PriceWaterhouseCoopers
PriceWaterhouseCoopers

AGM of MorphoSys Approves All Management Proposals

Annual General Meeting of MorphoSys AG Approves All Management Proposals MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that at the Company's Annual Shareholder Meeting on Tuesday, 4 June 2013, its shareholders approved the following ... [Published Big News Network - Jun 04 2013]
First reported Jun 03 2013 - Updated Jun 04 2013 - 5 reports

MorphoSys Pockets €22.5M in Antibody Licensing Deal with GSK

German firm could earn another €425M in milestones MorphoSys will pocket an up front payment of €22.5 million from GlaxoSmithKline (GSK) and could receive up to €425 million in development, regulatory, commercial and sales-based milestone payments as ... [Published Pharma-Mag - Jun 04 2013]
First reported Jun 03 2013 - Updated Jun 04 2013 - 2 reports
MorphoSys AG
MorphoSys AG

MorphoSys Signs Global License Agreement with GSK for Anti-Inflammatory Program

MorphoSys to receive committed and success-based payments of up to €445 million and double-digit royalties on net sales. ... [Published Technology Networks - Jun 04 2013]
First reported Jun 03 2013 - Updated Jun 03 2013 - 1 reports

MorphoSys Nabs GSK As Latest Partner For RA Drug

The British pharma is expanding its portfolio in rheumatoid arthritis through a mid-stage tie-up with German biotech MorphoSys. GSK will take over all development of the antibody and could pay milestones up to €425 million. ... [Published The Rose Sheet - Jun 03 2013]
First reported Jun 03 2013 - Updated Jun 03 2013 - 7 reports

MorphoSys Signs Global License Agreement with GlaxoSmithKline for Anti-Inflammatory Program MOR103 and Increases...

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that they have entered into a global agreement with GlaxoSmithKline (GSK) to develop and commercialize MOR103. MOR103 is MorphoSys's proprietary HuCAL-derived antibody against GM-CSF, ... [Published BioM - Jun 03 2013]
First reported Jun 03 2013 - Updated Jun 03 2013 - 1 reports

MorphoSys to Present at Five Investor Conferences in June

MorphoSys AG / . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. The management of MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will present at five upcoming international ... [Published Market Wire - Jun 03 2013]
First reported Jun 03 2013 - Updated Jun 03 2013 - 1 reports

MorphoSys to Present at Five Investor Conferenc...

MorphoSys AG / MorphoSys to Present at Five Investor Conferences in June . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.The management of MorphoSys AG (FSE: MOR; Prime Standard ... [Published Best Invest - Jun 03 2013]
First reported Jun 03 2013 - Updated Jun 03 2013 - 1 reports

MorphoSys outlicenses antibody to GSK

MorphoSys AG has successfully outlicensed its first proprietary antibody, MOR103 for rheumatoid arthritis, to GlaxoSmithKline Plc in a deal potentially valued at €445.5 million. The German company is set to receive an upfront payment of €22.5 million ... [Published MedNous - Jun 03 2013]

Quotes

"We're looking for access to a special asset or special expertise that can support assets we have and can develop into future drugs" said Miguel Barbosa, leader of immunology research and scientific partnership strategy at Janssen Research & Development L L C , a subsidiary of Johnson...
Large, small drug firms join for profitable results [Published Individual.com - Jun 08 2013]
"The preclinical and clinical data we have generated show that MOR103 has the potential to offer new treatment options for rheumatoid arthritis,” said Dr. Arndt Schottelius, chief development officer of MorphoSys."
MorphoSys, GSK ink license agreement [Published Center Watch - Jun 07 2013]
Dr FrankFrank Mathias, Vorstandsvorsitzender der Medigene AG, kommentiert: "Medigene konnte in den vergangenen Monaten über wichtige Neuigkeiten und Fortschritte im operativen Geschäft berichten, z. B über die weltweite Verpartnerung von EndoTAG(®)-1 sowie neue Zulassungen und Markteinführungen von Veregen(®). Unseren Aktionären schlagen wir nun eine Kapitalherabsetzung vor, um unsere Aktie und die strategische Handlungsfähigkeit unseres Unternehmens weiter zu stärken. Zudem soll das Aufsichtsratsgremium der Unternehmensgröße angepasst werden. Es stehen hochqualifizierte Kandidaten mit langjähriger Erfahrung in der deutschen und internationalen Biotechnologiebranche für dieses Gremium zur Verfügung. Wir freuen uns darauf, unsere Vorschläge in der anstehenden Hauptversammlung unseren Aktionären zur Beschlussfassung vorzulegen."
Medigene plant Herabsetzung des Grundkapitals sowie Verkleinerung und Neuwahl des Aufsichtsrats [Published Quoteline - Jun 05 2013]
Dr FrankFrank Mathias, Chief Executive Officer of Medigene AG, comments: "During the past few months, Medigene reported important news and progress in its operative business, for example the global partnership for EndoTAG®-1, as well as new market approvals and launches of Veregen®. We now propose to our shareholders a capital reduction in order to further strengthen our share price and our capacity to act strategically. In addition, the Supervisory Board should be adapted to the size of our company. We are delighted to have a selection of highly qualified candidates with many years of experience in the German and international biotech industries and we look forward to presenting our proposals to our shareholders at the upcoming annual general meeting."
MEDIGENE AG: announces capital reduction and nomination of new members to a reduced Supervisory B ... [Published 4 Traders - Jun 05 2013]

More Content

All (77) | News (47) | Reports (0) | Blogs (9) | Audio/Video (0) | Fact Sheets (0) | Press Releases (21)
sort by: Date | Relevance
Morphosys Partnering 2005-2013 - new company pr... [Published TransWorldNews - Jun 15 2013]
Large, small drug firms join for profitable res... [Published Individual.com - Jun 08 2013]
MorphoSys, GSK ink license agreement [Published Center Watch - Jun 07 2013]
[Glaxo] gets global rights to [MorphoSys]’ rheu... [Published BioPortfolio - Jun 07 2013]
Glaxo, MorphoSys in $577M RA Deal [Published Drugs.com - Jun 06 2013]
Heptares to Present at Upcoming Biotech Industr... [Published SYS-CON Media - Jun 06 2013]
Heptares to Present at Upcoming Biotech Industr... [Published TickerTech.com - Jun 06 2013]
GSK buys rights to MorphoSys’ arthritis antibody [Published PMLive - Jun 06 2013]
GSK to develop and commercialize MorphoSys HuCA... [Published Big News Network - Jun 05 2013]
Medigene plant Herabsetzung des Grundkapitals s... [Published Quoteline - Jun 05 2013]
MEDIGENE AG: announces capital reduction and no... [Published 4 Traders - Jun 05 2013]
GSK to develop and commercialize MorphoSys' HuC... [Published PBR - News - Jun 05 2013]
AGM of MorphoSys Approves All Management Proposals [Published Big News Network - Jun 04 2013]
MorphoSys Pockets €22.5M in Antibody Licensing ... [Published Pharma-Mag - Jun 04 2013]
Nine GSK, Stiefel Products Experience Renaissance [Published Genetic Engineering News - Jun 04 2013]
Annual General Meeting of MorphoSys AG Approves... [Published Marketwire - Breaking News Releases - Jun 04 2013]
GSK taps MorphoSys for rheumatoid arthritis can... [Published Pharma Times - Jun 04 2013]
GSK taps MorphoSys for rheumatoid arthritis can... [Published Big News Network - Jun 04 2013]
MorphoSys Signs Global License Agreement with G... [Published Technology Networks - Jun 04 2013]
MorphoSys inks deal with GSK for anti-inflammat... [Published Drug Discovery News - Jun 04 2013]
MorphoSys Nabs GSK As Latest Partner For RA Drug [Published The Rose Sheet - Jun 03 2013]
GSK Grabs MorphoSys RA Candidate in Deal Worth ... [Published Genetic Engineering News - Jun 03 2013]
MorphoSys Signs Global License Agreement with G... [Published BioM - Jun 03 2013]
MorphoSys to Present at Five Investor Conferenc... [Published Market Wire - Jun 03 2013]
MorphoSys to Present at Five Investor Conferenc... [Published Best Invest - Jun 03 2013]
MorphoSys outlicenses antibody to GSK [Published MedNous - Jun 03 2013]
MorphoSys Sells Drug to Glaxo for $577 Million ... [Published BusinessWeek - Jun 03 2013]
GlaxoSmithKline grabs PhII rheumatoid arthritis... [Published FierceBiotech - Jun 03 2013]
Morphosys AG Signs Global Agreement with GlaxoS... [Published Reuters UK - Jun 03 2013]
MorphoSys Inks Global Agreement With GlaxoSmith... [Published RTTNews.com - Jun 03 2013]
1 2 3
In Focus
  •  
Simon Moroney, Claudia Gutjahr-Löser, Jens Holstein, [more]
  •  
GlaxoSmithKline plc, AbD Serotec, Bio-Rad Laboratories Incorporated, [more]
  •  
United States Patent And Trademark Office, FDA Food & Drug Administration, Vanderbilt University, [more]
  •  
Antibody, Rheumatoid Arthritis, Drugs, [more]
  •  
HuCAL, Slonomics, Gantenerumab, [more]
  •  
Munich (Germany), Planegg (Germany), Frankfurt am Main, [more]
  •  
Germany, United States, United Kingdom, [more]
  •  
Diseases, Narcotics, Medication, [more]
  •  
Construction, Banking & Financial Services, Health, [more]
Marketwire - Breaking News Releases, PBR - News, PharmaBiz, [more]
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
GSK to develop and commercialize MorphoSys' HuC... [Published PBR - News - Jun 05 2013]
GlaxoSmithKline (GSK) has agreed to assume responsibility for all development and commercialization of MorphoSys' proprietary HuCAL-derived antibody against GM-CSF, MOR103. ...
MorphoSys Pockets €22.5M in Antibody Licensing ... [Published Pharma-Mag - Jun 04 2013]
German firm could earn another €425M in milestones MorphoSys will pocket an up front payment of €22.5 million from GlaxoSmithKline (GSK) and could receive up to €425 million in development, regulatory, commercial and sales-based milestone payments as ...
Heptares Augments Business Development Capabili... [Published Pharma-Mag - May 24 2013]
Heptares Therapeutics, the leading GPCR drug discovery and development company, is pleased to announce that it has engaged Mr Akira Usui as a Consultant to augment the Company’s business development capabilities in Japan and other Asian territories. ...
MorphoSys reaches milestone in ophthalmology pr... [Published PBR - News - May 07 2013]
MorphoSys has reached a milestone in ophthalmology program for the development of HuCAL-derived, fully human antibody, with Novartis. ...
MorphoSys commences Phase 2 trial of MOR208 leu... [Published PBR - News - Apr 29 2013]
MorphoSys has commenced patient dosing in a Phase 2 trial of MOR208 to treat B-cell acute lymphoblastic leukemia (B-ALL). ...
1 2

Press Releases

sort by: Date | Relevance
Annual General Meeting of MorphoSys AG Approves... [Published Marketwire - Breaking News Releases - Jun 04 2013]
MorphoSys Signs Global License Agreement with G... [Published Marketwire - Breaking News Releases - Jun 03 2013]
MorphoSys Initiates Phase 2 Study of Anti-CD19 ... [Published Marketwire - Breaking News Releases - May 13 2013]
MorphoSys Announces First Scientific Publicatio... [Published Marketwire - Breaking News Releases - May 10 2013]
MorphoSys to Present at Four Investor Conferenc... [Published Marketwire - Breaking News Releases - May 08 2013]
1 2 3 4 5
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.